HIV in Human Genomes and TherapeuticsDa-Yong Lu1*, Ting-Ren Lu1, Nagendra Sastry Yarla2, Bin Xu3 and Jian Ding3
- *Corresponding Author:
- Lu DY
School of Life Sciences
Shanghai University, Shanghai 200444
E-mail: [email protected]
Received Date: June 01, 2017; Accepted Date: June 09, 2017; Published Date: June 16, 2017
Citation: Lu DY, Lu TR, Yarla NS, Xu B, Ding J (2017) HIV in Human Genomes and Therapeutics. HIV Curr Res 2: 121.
Copyright: © 2017 Lu DY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
One of the most interesting topics in the field of HIV/AIDS study is the possible relationship between HIV genetic penetrations and disease stages. One decade before, this kind of genomic information is difficult to achieve. Yet, the innovations of next generation sequencing (NGS) have changed this landscape. At present, new generations of bio-therapies target this undesired pathogenic pathways. In this article, we address the relationships between HIV-induced genomic changes across the history and different types of therapeutics have been testified since last decade—including integrate inhibitors, genome editing agents and therapeutic schedules. Future perspectives are also given.